Quick answers
- What is Nadofaragene firadenovec-vncg used for?
- The FDA-approved label (Adstiladrin, Ferring Pharmaceuticals Inc., March 24, 2026) says: “ADSTILADRIN ® is indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the side effects of Nadofaragene firadenovec-vncg?
- The “Adverse Reactions” section of the FDA label (Adstiladrin, Ferring Pharmaceuticals Inc., March 24, 2026) begins: “The most common (>10%) adverse reactions, including laboratory abnormalities (>15%), were glucose increased, instillation site discharge, triglycerides increased, fatigue, bladder spasm, micturition (urination urgency), creatinine increased, hematuria (blood in urine), phosphate decreased, chills, pyrexia (fever), and dysuria (painful urination).” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Nadofaragene firadenovec-vncg have a boxed warning?
- No. None of the 1 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Nadofaragene firadenovec-vncg?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
- Has Nadofaragene firadenovec-vncg been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Nadofaragene firadenovec-vncg?
- 1 company lists prescription products of Nadofaragene firadenovec-vncg in the FDA NDC Directory, including Ferring Pharmaceuticals Inc.
What Nadofaragene firadenovec-vncg is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
ADSTILADRIN ® is indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. …
— FDA label: Adstiladrin, Ferring Pharmaceuticals Inc., effective March 24, 2026. Read the full label on DailyMed →
Label quoted: the one for the most common form (suspension, intravesical), Adstiladrin, Ferring Pharmaceuticals Inc.; it covers 1 product in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
Nadofaragene firadenovec-vncg side effects
Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.
The most common (>10%) adverse reactions, including laboratory abnormalities (>15%), were glucose increased, instillation site discharge, triglycerides increased, fatigue, bladder spasm, micturition (urination urgency), creatinine increased, hematuria (blood in urine), phosphate decreased, chills, pyrexia (fever), and dysuria (painful urination).
Read more of this section
(6.1) To report SUSPECTED ADVERSE REACTIONS, contact Ferring Pharmaceuticals at 1-888-337-7464 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of ADSTILADRIN was evaluated in Study CS-003, a multicenter, single-arm, open-label study in 157 U.S. patients [see Clinical Studies (14)] with high-risk BCG‑unresponsive NMIBC, 107 of whom had BCG-unresponsive carcinoma in situ (CIS) with or without papillary tumors. Patients received 75 mL (3 x 10 11 vp/mL) ADSTILADRIN administered intravesically once every 3 months for up to 12 months [see Clinical Studies (14)]. All patients with an absence of high-risk recurrence or progression were offered continued treatment every 3 months beyond 12 months. The median number of instillations of ADSTILADRIN was 2 (range 1 to 5). Serious adverse reactions occurred in 11% of patients who received ADSTILADRIN. Serious adverse reactions occurring in >1% of patients included coronary artery disease and hematuria (blood in urine). Permanent discontinuation of ADSTILADRIN due to an adverse reaction occurred in 3 (1.9%) patients. Adverse reactions that resulted in permanent discontinuation of ADSTILADRIN included bladder spasm instillation site discharge, and benign neoplasm of the bladder. Dosage interruptions of ADSTILADRIN due to an adverse reaction occurred in 54 (34%) patients. Adverse reactions in >10% of patients that required dosage interruption included instillation site discharge, bladder spasm, and micturition urgency. The most common (>10%) adverse reactions, including laboratory abnormalities (>15%), were glucose increased, instillation site discharge, triglycerides increased, fatigue, bladder spasm, micturition (urination) urgency, creatinine increased, hematuria (blood in urine), phosphate decreased, chills, dysuria, and pyrexia (fever). Tables 1 and 2 summarize adverse reactions and laboratory abnormalities, respectively, in patients on ADSTILADRIN in CS-003. Clinically relevant adverse reaction in <10% of patients who received ADSTILADRIN include syncope (fainting) (1.3%). Table 1: Adverse Reactions (>10%) in Patients with NMIBC in CS-003 Adverse Reaction Graded per NCI CTCAE v4.03; there were no Grade 4 or 5 reactions.
Table from the label
| Adverse ReactionGraded per NCI CTCAE v4.03; there were no Grade 4 or 5 reactions. | ||
|---|---|---|
| ADSTILADRINGrade 1 and 2(n=157)% | ADSTILADRINGrade 3(n=157)% | |
| General disorders and administration site conditions | - | - |
| Instillation site discharge | 33 | 0 |
| Fatigue | 24 | 0 |
| Pyrexia | 16 | 0 |
| Chills | 15 | 0 |
| Renal and urinary disorders | - | - |
| Bladder spasm | 20 | 1 |
| Micturition urgency | 19 | 1 |
| Hematuria | 17 | 1 |
| Dysuria | 16 | 0 |
— FDA label: Adstiladrin, Ferring Pharmaceuticals Inc., effective March 24, 2026. This is part of the section. Read the full label on DailyMed →
Nadofaragene firadenovec-vncg dosage
Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.
Important Administration Instructions ADSTILADRIN is for intravesical instillation only. ADSTILADRIN is not for intravenous use, topical use, or oral administration. Premedication with an anticholinergic is recommended before each instillation of ADSTILADRIN. (2.1) Administer ADSTILADRIN by intravesical instillation only. (2.1) ADSTILADRIN is not for intravenous use, topical use, or oral administration.
Read more of this section
(2) The dose is 75 mL of ADSTILADRIN at a concentration of 3 x 10 11 viral particles (vp)/mL, instilled once every three (3) months. (2.1) Allow ADSTILADRIN to be left in the bladder for 1 hour following instillation. (2.3) 2.1 Dose The recommended dose of ADSTILADRIN is 75 mL at a concentration of 3 x 10 11 viral particles (vp)/mL instilled once every three (3) months into the bladder via a urinary catheter [see Dosage and Administration (2.2)]. Premedication with an anticholinergic is recommended before each instillation of ADSTILADRIN. 2.2 Preparation and Handling ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy. Follow universal biosafety precautions for handling. Individuals who are immunosuppressed or immune-deficient, should not prepare, administer, or come into contact with ADSTILADRIN [see Warnings and Precautions (5)]. ADSTILADRIN is provided as a sterile frozen suspension. All four vials of ADSTILADRIN must be thawed and brought to room temperature (20°C to 25°C [68°F to 77°F]) prior to use. Do not expose the vials to higher temperatures (>25°C [77°F]). Protect from light. DO NOT refreeze. ADSTILADRIN may be moved between refrigerator and room temperature if the total storage time at each condition is not exceeded (24 hours at room temperature and 7 days refrigerated including thawing time). [see How Supplied/Storage and Handling (16)] WHEN THAWING IN WATER BATH Frozen ADSTILADRIN vials will thaw in approximately 25 minutes outside the cardboard nest when placed directly in a water bath maintained at 25°C [77ºF]. Place the vials in the water bath, ensuring that the water level is sufficient to cover the product within the vials. Following thawing, remove vials from the water bath and dry with a clean paper towel to remove any residual moisture prior to further handling. WHEN THAWING AT ROOM TEMPERATURE Frozen ADSTILADRIN vials will thaw in approximately 3 to 5 hours outside the cardboard nest when placed at room temperature (up to 25°C [77ºF]) (8 to 10 hours inside the nest). WHEN THAWING IN REFRIGERATOR Frozen ADSTILADRIN vials will thaw in approximately 4 to 5 hours outside the cardboard nest when placed in the refrigerator (up to 8°C [46ºF]) (11 to 13 hours inside the nest). Subsequent time for bringing thawed ADSTILADRIN to room temperature is approximately 2 hours 30 minutes outside of the cardboard nest (6 hours inside the nest). Inspection and Preparing ADSTILADRIN for instillation Visually inspect all 4 vials for visible particles and discoloration. The suspension is clear to slightly opalescent and may contain opalescent flecks. Do not use if visible particles or discoloration are observed. Mix gently. Do not shake.
— FDA label: Adstiladrin, Ferring Pharmaceuticals Inc., effective March 24, 2026. This is part of the section. Read the full label on DailyMed →
Nadofaragene firadenovec-vncg in pregnancy
Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.
Risk Summary Adequate and well-controlled studies with ADSTILADRIN have not been conducted in pregnant women. Animal reproductive and developmental toxicity studies have not been conducted with ADSTILADRIN. Advise pregnant women of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
— FDA label: Adstiladrin, Ferring Pharmaceuticals Inc., effective March 24, 2026. Read the full label on DailyMed →
When Nadofaragene firadenovec-vncg should not be used
Quoted from the “Contraindications” section of the FDA-approved label.
ADSTILADRIN is contraindicated in patients with prior hypersensitivity reactions to interferon alfa or to any component of the product [see Description (11)]. ADSTILADRIN is contraindicated in patients with hypersensitivity to interferon alfa or any component of the product. (4)
— FDA label: Adstiladrin, Ferring Pharmaceuticals Inc., effective March 24, 2026. Read the full label on DailyMed →
Forms and how it is given
| Dosage forms | Suspension |
|---|---|
| Route | Intravesical |
| Prescription products | 1 in the FDA NDC Directory |
| Brand names | Adstiladrin |
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Ferring Pharmaceuticals Inc.1 product
FDA approval history
- BLA: Biologics License Application: how a biologic medicine (made from living cells) is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| BLA125700 | — | Date not on file | — |
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 2644440, 2644445 |
|---|---|
| SPL set ID of the quoted label | 5ca20ed4-da4f-463c-ac2a-ccd6ab3774fa |
| FDA labels (SPL) | 1 |
| FDA applications | BLA125700 |
| Active ingredients (FDA) | NADOFARAGENE FIRADENOVEC |
Next steps
- Find a pharmacy near youAsk which price applies to you and whether your product is affected by a recall
- Latest FDA drug recallsAll medicines, newest first
- Ferring Pharmaceuticals Inc.Maker or distributor
- All prescription drugs A to ZSearch by generic, brand or Spanish name
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Adstiladrin, Ferring Pharmaceuticals Inc., effective March 24, 2026; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →